Cytomegalovirus enterocolitis in a patient with diffuse large B-cell lymphoma after chemotherapy with rituximab
- PMID: 17143963
- PMCID: PMC4087505
- DOI: 10.3748/wjg.v12.i45.7391
Cytomegalovirus enterocolitis in a patient with diffuse large B-cell lymphoma after chemotherapy with rituximab
Abstract
Rituximab has been associated with the development of cytomegalovirus enterocolitis in immunosuppressed patients. A 51-year-old patient with diffuse large B-cell lymphoma who received a conditioning chemotherapy regimen (RCVP and RICE) consisting of rituximab before bone marrow transplantation went on to develop cytomegalovirus enterocolitis. This supports evidence from previously described cases that rituximab may be associated with cytomegalovirus enterocolitis.
Comment on
-
Cytomegalovirus gastritis after rituximab treatment in a non-Hodgkn's lymphoma patient.World J Gastroenterol. 2006 Mar 28;12(12):1978-9. doi: 10.3748/wjg.v12.i12.1978. World J Gastroenterol. 2006. PMID: 16610013 Free PMC article. No abstract available.
References
-
- Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268–276. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
